BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...LianBio. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Mar 30, 2021
Management Tracks

Li departs LianBio as CEO; plus Xilio, Myriad, OKYO and Intravacc

...LinkedIn page. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...primarily in China. His previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...the therapy’s efficacy, but also suggested FDA had presented biased data analyses through collaboration with Biogen.Ambrx’s...
...Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics AG Assembly Pharmaceuticals Inc. Biogen Inc. Pfizer Inc. Ambrx Inc. Decibel...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...developing ARX720, a relaxin derivative from partner Ambrx Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...primarily in China. His previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

...one of the models. At least two FGF21 analogs are in clinical testing. Pegbelfermin from Ambrx Inc....
BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

...patients. There are at least two other FGF21 analogs in development. Bristol-Myers Squibb Co. and Ambrx Inc....
...and Institutions Mentioned 89bio Inc., San Francisco, Calif. Akero Therapeutics Inc., South San Francisco, Calif. Ambrx Inc....
BioCentury | Apr 6, 2019
Finance

Everybody up

...is being tested in other indications, is the company’s only product. Companies and Institutions Mentioned Ambrx Inc....
Items per page:
1 - 10 of 117
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

...LianBio. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Mar 30, 2021
Management Tracks

Li departs LianBio as CEO; plus Xilio, Myriad, OKYO and Intravacc

...LinkedIn page. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Nov 20, 2020
Deals

China in-licensing play LianBio follows $310M crossover round with broad Pfizer deal

...primarily in China. His previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Nov 10, 2020
Finance

Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more

...the therapy’s efficacy, but also suggested FDA had presented biased data analyses through collaboration with Biogen.Ambrx’s...
...Thursday’s close at $15.90.TARGETSOTOF – Otoferlin BC Staff Inmagene Biopharmaceuticals Co. Ltd. Memo Therapeutics AG Assembly Pharmaceuticals Inc. Biogen Inc. Pfizer Inc. Ambrx Inc. Decibel...
BioCentury | Oct 29, 2020
Finance

Perceptive-backed in-licensing play LianBio to cast a wide net with $310M crossover round

...Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

...developing ARX720, a relaxin derivative from partner Ambrx Inc....
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...primarily in China. His previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc....
BioCentury | Feb 26, 2020
Distillery Therapeutics

Boosting FGF21 signaling to treat pancreatitis

...one of the models. At least two FGF21 analogs are in clinical testing. Pegbelfermin from Ambrx Inc....
BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

...patients. There are at least two other FGF21 analogs in development. Bristol-Myers Squibb Co. and Ambrx Inc....
...and Institutions Mentioned 89bio Inc., San Francisco, Calif. Akero Therapeutics Inc., South San Francisco, Calif. Ambrx Inc....
BioCentury | Apr 6, 2019
Finance

Everybody up

...is being tested in other indications, is the company’s only product. Companies and Institutions Mentioned Ambrx Inc....
Items per page:
1 - 10 of 117